Business Description
OncoSil Medical Ltd
ISIN : AU000000OSL3
Description
OncoSil Medical Ltd is an Australian based medical device company focused on localized radiation treatments for patients with pancreatic and bile duct cancer. The product includes OncoSil, a silicon and phosphorus (p32) beta emitter radiation therapy for the treatment of pancreatic cancer.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 45.72 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.58 | |||||
Beneish M-Score | -2.92 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.6 | |||||
3-Year EPS without NRI Growth Rate | -21.6 | |||||
3-Year FCF Growth Rate | -26 | |||||
3-Year Book Growth Rate | -37 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -70.05 | |||||
12-1 Month Momentum % | -50.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.74 | |||||
Quick Ratio | 2.74 | |||||
Cash Ratio | 2.14 | |||||
Days Sales Outstanding | 757.49 | |||||
Days Payable | 299.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.2 | |||||
Shareholder Yield % | -21.07 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -683.26 | |||||
Operating Margin % | -5441 | |||||
Net Margin % | -4898.75 | |||||
FCF Margin % | -4283.11 | |||||
ROE % | -178.08 | |||||
ROA % | -137.57 | |||||
ROIC % | -2648.47 | |||||
ROC (Joel Greenblatt) % | -5607.69 | |||||
ROCE % | -187.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6 | |||||
EV-to-EBIT | -3.28 | |||||
EV-to-EBITDA | -3.32 | |||||
EV-to-Revenue | 169.97 | |||||
EV-to-FCF | -3.95 | |||||
Earnings Yield (Greenblatt) % | -30.49 | |||||
FCF Yield % | -22.62 |